Bharat Biotech reveals positive data from animal trial of Covaxin
Category: #health  By Saipriya Iyer  Date: 2020-09-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bharat Biotech reveals positive data from animal trial of Covaxin

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal trial phase, 20 monkeys in the country were studied, being administered two doses of the Covaxin BBV 152, an inactivated SARS-CoV-2 vaccine. These monkeys were administered with 2 doses of the vaccine in a 14-day span, where the results showed strong immune responses and a significant reduction in virus replication in the throat, nasal cavity, and lung tissues. Bharat Biotech has reportedly stated that the trial data also has demonstrated the protective efficacy of the vaccine in a live viral challenge model, increasing SARS-CoV-2 specific IgG & neutralizing antibodies.

The selected monkeys were divided into 4 groups, out of which, 3 groups were administered the vaccination while the remaining group was administered with placebo. According to the results, the 3 vaccinated groups showed no signs of pneumonia, while the placebo group had evidences of pneumonia.

Sources familiar with the matter also have stated that Covaxin has significantly developed a robust immune response, thereby preventing the disease among primates upon high exposure to the virus.

In the Phase I/II clinical study, Bharat Biotech and ICMR (Indian Council of Medical Research) have conducted the vaccine trial among 1,125 subjects at 12 institutes in India, including PGIMS in Rohtak, Nizam’s Institute of Medical Sciences in Hyderabad, King George Hospital in Visakhapatnam, and AIIMS (All India Institute of Medical Sciences) in New Delhi & Patna. Additionally, in the Phase I trial conducted in India, the vaccine candidate demonstrated immunogenicity and high efficacy among non-human primates. There have also been no side-effects of Covaxin observed in the animal trials.

PGI (Post Graduate Institute) Rohtak has previously stated that it will commence the Phase II human trial of Bharat Biotech’s Covaxin.

Source credit:

https://english.jagran.com/india/indias-coronavirus-vaccine-candidate-covaxin-shows-encouraging-results-in-animal-trial-10016670



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Paradigm moves on to phase three trials of Zilosul after EMA’s approval
Paradigm moves on to phase three trials of Zilosul after EMA’s approval
By Saipriya Iyer

According to reliable sources, Paradigm Biopharmaceuticals Ltd. has made headway towards the phase three trials of their drug Zilosul, which is used for the treatment of arthritis.

...

Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
Vela Diagnostics gains EUA for ViroKey™ SARS-CoV-2 RT-PCR test v2.0
By Saipriya Iyer

Vela Diagnostics has recently announced that the U.S. FDA has granted an EUA (Emergency Use Authorization) for its ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 in the United States. This automated p...

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...